New service using acute lung injury a rodent model

  • 2020.07.22

We are pleased to announce the launch of new service using the Lipopolysaccharides (LPS)-induced acute lung injury (ALI) model as an ARDS model.


One of the most commonly used rodent models of ALI/ARDS is administration of lipopolysaccharide (LPS). In experimental ALI, the lung parenchyma is damaged by the generation and release of proteases and reactive oxygen and nitrogen species produced by activated lung macrophages and transmigrated neutrophils in the  interstitial and alveolar compartments. The end results are microvascular injury and diffuse alveolar damage, which are also features in patients with ALI/ARDS.


Also, you can see symptoms shown in COVID-19 patients in this model such as significant increase of IL-6 and neutrophil inflammatory cells.


LPS-induced animal models highlight ways to explore mechanisms of multiple diseases and provide useful information on the discovery of novel biomarkers and drug targets.


Please feel free to contact us if you are interested in the pharmacology study using this model.